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Introduction
Epilepsy is one of the most common 
neurological disorders, occurring in the range 
of 0.5-1.0% of the general population.1 It is 
a heterogeneous condition and classification 
of epileptic seizures by the International 
League Against Epilepsy (ILAE), the most 
widely adopted scheme, classifies seizures 
according to seizures symptoms and not 
underlying aetiology.  A revised framework for 
the Classification of the Epilepsies, designed 
to work with the classification of seizure 
types, which considers levels of diagnosis: 
seizure type, epilepsy type (focal, generalized, 
combined generalized and focal, unknown) 
and epilepsy syndrome has just been approved 
by ILAE2 (see Figure 1). Most persons with 
epilepsy first develop the condition in 
childhood with approximately 45 per 100,000 
children per year developing new-onset 
epilepsy.3 Between 2% and 4% of all children 
in Europe develop at least one convulsion 
associated with a febrile illness before the age 
of 5 years. The highest incidence of epilepsy 
is in the first year of life. Neonatal seizures 
occur in ~1.5% of neonates, febrile seizures 
in 2-4% of young children, and epilepsy in 
up to 1% of children and adolescents.4 The 
paediatric population poses a challenge to the 
individualisation of drug therapy and this is 
even more so in epilepsy.  
In Malta, epilepsy is known as a ‘Schedule 
V’ condition, meaning that it is one of 
the medical conditions in which patients 
can obtain free drug therapy through the 
Maltese National Health Service (Social 
Security Act, 2014). At a local level only 
specifically branded drugs are used in the 
pharmacological management of epilepsy.  In 
a Maltese study of 220 children with epilepsy 
by Soler5 the point prevalence rate of active 
epilepsy in children up to the age of 15 
years in 1999 was 2.22 per 1000 population 
in females and 2.61 per 1000 in males up 
to the age of 15 years, with no significant 
difference between males and females 
(p=0.25). Similar findings regarding the larger 
number of boys with epilepsy are found in a 
number of studies. In Soler’s study, 47% of 
children suffered from generalized seizures 
which were more common in infants and 
pre-school children, while 37% had partial 
seizures. Motor seizures were present in 30% 
of children while 30% had complex partial 
seizures with secondary generalization. There 
was equal prevalence of both generalised 
and partial seizures in school-aged children. 
Twenty-three per cent of children (all up 
to the age of 5 years) also had a history of 
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febrile seizures (17% simple seizures, 5% 
complex febrile seizures). In Soler’s study, 
2% of children had infantile spasms, 30% 
had major motor seizures, 15% had absence 
seizures, 37% had partial seizures, 15% had a 
mixtures of seizure phenotypes, whereas 1% 
of seizures were unclassified. 
Pharmacological therapy with antiepileptic 
drugs (AEDs)
Pharmacological therapy with antiepileptic 
drugs (AEDs) aims to minimize the 
frequency of epileptic seizures with minimal 
side effects.6 AEDs are used as long term 
adjunctive therapy or as monotherapy in 
epilepsy and can result in seizure freedom 
for around 70% of patients. The target in the 
treatment of epilepsy is to control seizures 
with low or no adverse effects. About 20 % of 
paediatric epilepsy population are not seizure 
free despite AEDs therapy either as mono or 
poly therapy.7 Before 1993, phenobarbital, 
phenytoin, carbamazepine, valproic acid, 
ethosuximide, and the benzodiazepines 
were the only antiepileptic drugs used in 
the treatment of epilepsy in children. The 
approval of new generation AEDs expanded 
the treatment options for epilepsy for 
children and adults.  These new generation 
AEDs have equal efficacy with better 
tolerability, pharmacokinetic properties, and 
side effect profiles compared to the older 
AEDs.8 
The first-generation AEDs (phenytoin, 
phenobarbital, carbamazepine, ethosuximide, 
primidone, and valproic acid) were mostly 
developed before the 1960s, and they are 
still used, although they are associated 
with serious side effects and problems in 
the individualisation of drug therapy due 
to narrow therapeutic indices. They are 
also associated with numerous drug-drug 
interactions due to enzyme induction and 
enzyme inhibition properties and even non-
linear kinetics in some case.  
In 1990s, second or third generation 
AEDs were developed (felbamate, gabapentin, 
lamotrigine, levetiracetam, oxcarbazepine, 
pregabalin, rufinamide, stiripentol, tiagabine, 
topiramate, vigabatrin, zonisamide, 
eslicarbazepine acetate, and lacosamide) 
in attempts to address the shortcomings of 
the older AEDs and improve the risk-benefit 
ratio.9 Consequently, the treatment options 
of epilepsy have been expanded, however 
even this novel therapy is still associated 
with significant shortcomings, especially for 
paediatric populations.
Felbamate was approved by FDA to be used 
in United Stated in 1993. It shows efficacy in 
Lennox-Gastaut syndrome and partial seizures 
in children.10 Aplastic anemia and hepatic 
failure are life-threatening adverse side effects 
of felbamate. Gabapentin was approved in 
1993 as adjunctive therapy in the treatment 
of partial seizures with or without secondary 
generalization as adjunctive therapy in 
patients 3 years and older.  It is also effective 
in some children with refractory partial seizures 
and in controlling seizures associated with 
benign childhood epilepsy with centrotemporal 
spikes.11 Lamotrigine (LTG) was approved in 
the USA in 1994 for the treatment of focal 
seizures, then in 1998 it was approved to 
be used as adjunctive treatment of Lennox-
Gastaut syndrome.  LTG is now considered as 
first line drug for focal seizures and generalized 
tonic-clonic seizures. Oxcarbazepine was 
approved in 2000 for the treatment of 
partial-onset epilepsy as monotherapy or 
polytherapy in patients aged 4 years or older. 
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It shows equal efficacy to phenytoin with 
better tolerability in a randomized study 
in children.12 Levetircetam was approved 
in 1999 for the treatment of partial-onset 
seizures in adults as adjunctive therapy. 
It shows high efficacy and tolerability 
in refractory mixed seizure in children.13 
Tiagabine was approved in 1997 for the 
treatment of partial seizures in patients 12 
years of age and older as adjunctive therapy. 
Topiramate was approved 1997 as adjunctive 
therapy for the treatment of primary 
generalized tonic-clonic seizures, partial-
onset seizures, and seizures associated 
with Lennox-Gastaut syndrome in patients 
older than 2 years.  Vigabatrin was initially 
licensed in 1989 however due to its visual 
toxicity it was eventually with withdrawn.14 
Zonisamide was approved in 2000 for the 
treatment of partial-onset seizures.
Local practice for the treatment of 
epilepsy in Malta follows the Guidelines 
issued by the UK’s National Institute of 
Clinical Excellence (NICE)15 (see Table 
1).  NICE guidelines also recommend that 
patients who do not respond to adjunctive 
drugs after an adequate trial of first line 
AED has been unsuccessful are referred to 
tertiary centres for evaluation in adjunction 
to consideration of further pharmacotherapy. 
An adequate trial of AED is one in which an 
AED (preferably one recommended by the 
guidelines) has been used at a therapeutic 
dose (preferably confirmed by means of 
therapeutic monitoring of serum blood 
levels), for sufficient duration of time, in 
a patient who has been adherent to drug 
therapy. If this trial has not been sufficient 
to provide seizure control, another drug 
may be added. If the first drug attempted 
has not been well-tolerated by the patient, 
one may change initial monotherapy to 
another drug which is better tolerated. In 
some circumstances, one may need to seek 
the optimum balance between, seizure 
control, drug efficacy, safety, tolerability 
and patient quality of life. NICE guidelines 
recommend that in the case of adults, AED 
therapy is initiated on the recommendation 
of a specialist, but in the case of children, 
NICE guidelines recommend that AED 
therapy should be initiated by a specialist 
directly, in the context of communication, 
discussion and explanation to the patient 
and their carers/family, as appropriate. The 
decision with regard to which AED to use 
as initial therapy depends on the nature of 
the presenting epilepsy syndrome or type 
of seizure if the diagnosis of an epilepsy 
syndrome is unclear. Usually, AED therapy is 
initiated after a second seizure. It is initiated 
after the first seizure if there is an associated 
neurological deficit, there is clear evidence of 
epileptic activity on electroencephalography, 
the risk of further seizures is deemed to be 
unacceptable or there is a structural brain 
lesion on cerebral radiographic imaging.15 
Pharmacokinetics of AEDs
Understanding differences in the 
pharmacokinetics (PK) and /or 
pharmacodynamics (PD) between children 
and adults and also between children 
of different ages is important in the 
individualisation of drug therapy in epilepsy. 
Pharmacokinetic processes (absorption, 
distribution, metabolism, and elimination) 
and pharmacodynamic effects are affected by 
developmental changes in childhood.16 For 
example, pH of intra-gastric fluid is higher in 
neonates than in adults and this can cause a 
decrease in the bioavailability of weak acidic 
AEDs such as phenytoin and phenobarbital 
and subsequently higher doses is needed.17 
Additionally, the delayed gastric emptying 
time in neonates slows the absorption of 
some drugs. Many studies have shown that 
the metabolizing enzyme capacity is changed 
during childhood and maturation of the 
enzyme systems occur at different rates. Thus, 
total drug clearance is highest in neonates, 
and declines with age reaching adult values 
in adolescence.  
This is also the case for AEDs since many 
studies have indicated that the apparent 
oral clearance of AEDs is higher in children 
compared with adults.18 Moreover, Perucca 
pointed out that the data available indicates 
that clearance of novel AEDs in children 
is increased by 20-170%, depending on 
the drug and patient’s characteristics.  
Furthermore, the distribution of drugs in 
children is influenced by the changes in the 
body composition which is depending also 
on the age. For instance, the increase in 
body water:body fat ratio in neonates and 
infants leads to an increase in the volume 
of distribution for hydrophilic AEDs such as 
phenobarbital. 17
The influence of such developmental 
changes in childhood on PK of a drug is 
Table 1: Drugs used in the management of more common epilepsies (adapted from 
2013 NICE guidelines for the management of epilepsy)15
TYPE OF SEIZURE AED RECOMMENDED BY NICE 
GUIDELINES
TYPE OF THERAPY 
(INITIAL THERAPY OR 
ADJUNCTIVE THERAPY)
Focal Lamotrigine, Carbamazepine Initial monotherapy
Refractory focal Carbamazepine, Clobazam, 
Gabapentin, Lamotrigine, 
Levetiracetam, Oxcarbazepine, 
Sodium valproate, Topiramate
Adjunctive
Generalised tonic-clonic Valproate, Lamotrigine, 
Carbamazepine, Oxcarbazepine
Initial monotherapy
Refractory generalised 
tonic-clonic
Lamotrigine, Levetiracetam, Sodium 
valproate, Topiramate
Adjunctive
Absence Ethosuximide, Sodium valproate, 
Lamotrigine
Initial monotherapy
Myoclonic Sodium valproate, Levetiracetam, 
Topiramate
Initial monotherapy
Tonic or atonic Sodium valproate Initial monotherapy
Refractory tonic or 
atonic
Lamotrigine Adjunctive
Infantile spasms Vigabatrin or (if not due to tuberous 
sclerosis) add steroid
Initial therapy
Idiopathic generalised 
epilepsy
Sodium valproate, Lamotrigine, 
Topiramate
Initial therapy
Refractory idiopathic 
generalised epilepsy
Sodium valproate, Lamotrigine, 
Levetiracetam, Topiramate
Adjunctive therapy
Juvenile myoclonic 
epilepsy
Sodium valproate Initial monotherapy
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investigated using plasma drug concentration 
time profiles, which require measurements of 
drug concentrations from biological matrixes.  
Thus, these age-related PK and PD differences 
are rarely reported in the literature, since for 
ethical reasons, children are rarely included 
in clinical trials. Investigators usually have 
access only to a small number and volumes 
of blood samples which makes interpretation 
and modelling of the pharmacokinetics more 
difficult.16 
In addition, it is estimated that between 
50 and 90% of medicinal products used 
in paediatric population have never been 
specifically evaluated for use in that group. 
The absence of suitable authorised medicinal 
products to treat conditions in children is due 
to the fact that pharmaceutical companies 
do not perform the necessary research and 
development to adapt medicinal products to 
the needs of the paediatric population.  The 
use of off-label and unauthorised products 
with the associated risks on inefficacy and/
or adverse reactions is the only alternative 
solution for the physician to treat paediatric 
patients.18 The current use of many AEDs 
in children is off-label and is based on the 
safety and efficacy derived from adult trials 
and from smaller uncontrolled studies in 
children that provide early pharmacokinetic 
data.19 Most paediatric epileptologists have, 
to date used, ad hoc reasoning in the design 
of dosage regimens for AEDs in children. This 
may cause therapeutic failure and occurrence 
of severe adverse effects.  
Pharmacokinetics of the new antiepileptic 
drugs 
Thus the availability of these new AEDs in 
the last decades promised an increase in 
the efficacy of pharmacological treatment 
for many types of epileptic seizures in 
children, with reduced adverse effects and 
less need for therapeutic drug monitoring. 
Yet various shortfalls were also seen 
with some of these novel AEDs especially 
due to some of their pharmacokinetic 
properties.  Pharmacokinetics is the 
study of the time course of a drug in the 
body, basically the liberation, absorption, 
distribution, metabolism and elimination 
of the drug. The pharmacokinetics of a 
drug vary from one patient to another 
due to several factors such as genetic 
factors, age, concomitant treatment, 
physiological and pathophysiological 
conditions such as pregnancy and impaired 
function of the liver and the kidneys.20 This 
pharmacokinetics variability results in altered 
dosage requirements.  Thus an inclusive 
understanding of pharmacokinetic properties 
of AEDs and the factors which contribute to 
their pharmacokinetic variability is essential 
for the correct use of AEDs in clinical 
practice.21 
Felbamate shows linear kinetics 
in children and adults during mono or 
polytherapy.22 The metabolism of felbamate 
is enhanced by enzyme-inducing AEDs such 
as phenobarbital, phenytoin, primidone and 
carbamazepine.  Gabapentin’s bioavailability 
decreases with increasing dosage, possibly 
because of saturation of the transporter 
system.23 Lamotrigine (LTG) clearance in 
infants below the age of 2 months is lower 
than in older infants. Lamotrigine clearance 
is influenced by enzyme inducing and 
enzyme inhibiting AEDs. Enzyme inducing 
increases LTG clearance in children to 
1.8ml/min/kg whereas; enzyme inhibiting 
decreases LTG clearance to 0.67 ml/min/
kg.24 Levetiracetam is mostly eliminated 
unchanged in the urine (66%) and 27% 
as inactive metabolites.25 Oxcarbazepine 
is a prodrug and is metabolised to the 
two equipotent pharmacologically active 
enantiomers of a monohydroxy derivative 
(MHD).26 Enzyme inducing AEDs (phenytoin, 
Phenobarbital and carbamazepine) enhance 
the metabolism of MHD and decrease 
its serum concentrations. Tiagabine is 
displaced by valproic acid from its serum 
protein binding sites.26 Co-administration of 
enzyme-inducing AEDs decreases topiramate 
half-life to 12h, increase topiramate 
clearance and subsequently its serum 
concentrations decreased to 50%.27 The 
half-life of zonisamide is 50-70 h during 
monotherapy, and it is reduced to 25-35 hrs 
with co-administration with enzyme inducing 
AEDs. Clearance of zonisamide is higher in 
children compared to adults, and children 
require higher doses to achieve the serum 
concentrations as that in adults.18  
Thus, overall, new AEDs are negligibly 
bound to plasma proteins, except tiagabine 
which is over 95% bound to plasma proteins. 
The clearance of the new AEDs has also been 
found to be higher in children than in adults 
and thus dosage adjustment is required in 
paediatric population, which is not only 
weight-based. Gabapentin and vigabatrin 
are eliminated primarily through renal 
excretion and therefore, show low drug-drug 
interaction potential.  On the other hand, 
the hepatic metabolism of several of the 
new AEDs such as lamotrigine, topiramate, 
oxcarbazepine, tiagabine, and felbamate is 
accelerated by enzyme inducing enzymes, 
including some of the traditional AEDs.  
Moreover, the metabolism of lamotrigine is 
inhibited by valproic acid.  
AED use in Malta
In a study carried out by Scerri28 valproate was 
found to be the most commonly prescribed 
conventional AED (65%) in the paediatric 
population in Malta. This was followed by 
carbamazepine (24%).  Lamotrigine was also 
the most commonly prescribed of the newer 
AEDs (16%) in Soler’s study and in 19.7% of 
cases in Scerri’s study.  It may be that the use 
of lamotrigine and levetiracetam (both newer 
AEDs) may have increased in comparison 
to carbamazepine use, possibly because of 
the efficacy, safety and tolerability profile 
of newer AEDs and the relative lack of drug 
interactions. 
In Soler’s study5, the main type of AED 
therapy was monotherapy (in 70% of cases 
i.e. 144 children), while 21% were on poly-
drug therapy. The findings of predominant 
AED monotherapy were also described by 
Dörks et al in their 2013 German study29 
and Nicholas et al in their 2012 UK study30 
which revealed that more patients were on 
monotherapy compared to poly-drug therapy 
in the study populations concerned.  It is 
significant that in the studies in which AED 
monotherapy was the main type of therapy 
as well as the studies reporting a dominant 
use of multiple drugs, a common AED in 
all the studies in which the main AED used 
was reported, was valproate. This could be 
because valproate has been used for a long 
time and clinicians have good experience 
with it, but also because it has good efficacy 
and generic effects on multiple types of 
seizures. It is important to evaluate the role 
of drugs and their efficacy in the context 
of different genetic and environmental risk 
factors in populations, which may lead to 
a differential resistance to AEDs between 
different populations, especially in the 
context of specific genetic polymorphisms 
in different populations which alter a drug’s 
pharmacodynamic properties.
However, the use of monotherapy 
versus poly-drug therapy has a number of 
implications for patient management. The 
use of more than one AED could result in 
reduced quality of life, loss of function and 
impaired productivity. Poly-drug therapy is 
also associated with increased adverse drug 
reactions, worsening of mental function 
and aggressive behaviour in some patients, 
which can be a key variable in their adverse 
health-related quality of life scores. Poly-
drug therapy may also be associated with a 
complex dosing regimen which may also lead 
to poor adherence to AED therapy. It also 
increases the risk of drug toxicity.  
In Soler’s local study5, mean age at onset 
of epilepsy was of 5.3 years. In her study, 
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Soler also confirms that onset of epilepsy 
had commonly occurred by the time the child 
was 2 years old. These findings are important 
because age of onset of epilepsy has 
implications on prognosis for development. 
Persons with early onset epilepsy and longer 
duration of the condition perform poorly 
in neuropsychological tests carried out in 
adulthood, showing more generalised, far-
reaching and intrusive deficits in comparison 
to persons diagnosed with epilepsy over 
the age of 11 years, even when adjusting 
for confounders such as seizure frequency.31 
These findings emphasise the need for early 
diagnosis and optimal management of seizure 
disorders, especially in persons who are 
diagnosed earlier in life, so as to maximise 
their functional potential at a neurocognitive 
level, especially since drug efficacy studies 
reveal that 30% to 40% of persons with 
epilepsy remain uncontrolled despite 
pharmacotherapy.32 
Epilepsy affects multiple domains 
in a patient’s life, including work and 
employment, relationships, family and care 
providers. It is associated with organic, 
psychiatric and psychological morbidity, 
stigma, social isolation, cognitive difficulties, 
dependence on others and difficulties related 
to employment.33 Epilepsy is also associated 
with decreased life expectancy and increased 
mortality, with increased risk of suicide and 
accidental injury, and a general decrease in 
quality of life, especially in patients with 
active epilepsy who experience frequent 
seizures. Increased patient self-efficacy is 
associated with improved quality of life.34 
Support groups and social services may 
help empower patients with epilepsy, but 
these services may be under-utilised due 
to lack of awareness of their existence or 
due to stigma.35 In a 2006 survey of 907 
patients between the ages of 18 and 65 
years, antiepileptic drug (AED) monotherapy 
was associated with better quality of life 
than poly-drug therapy for the treatment of 
epilepsy.36 
Hermann et al. 31 described that cognitive 
impairment exists at baseline, prior to the 
initiation of AED therapy and that these 
impairments can be altered for better or for 
worse by AEDs. In a study by Meador et al, 
200536 using the Medical College of Georgia 
Delayed Paragraph Recall test, lamotrigine 
and gabapentin were not found to produce 
deterioration in recall, unlike carbamazepine, 
phenytoin and topiramate, which produced 
a 10% to 20% reduction in number of items 
recalled. A decrease in recall can have a 
profound impact on the well-being of a child 
sitting in a classroom, or an office worker, 
carrying out activities that rely on focus, 
attention and memory, with a decrease 
in quality of life as a result of impaired 
performance and achievement. This also 
shows us how complex the selection of AEDs 
can be, since one must consider multiple 
factors including formulation, concurrent drug 
therapies and comorbidities, dosage regimen, 
adherence to therapy, adverse effect profile 
and frequency, efficacy and likelihood of 
cognitive effects.
The European task force for drug 
development in children (TEDDY) was 
developed as part of the 6th European 
Framework for Research and Development 
between 2005 and 2010, with the cooperation 
of eleven countries seeking to develop 
new drug therapies to treat a variety of 
illnesses.37 TEDDY recommended research 
on 21 Antiepileptic drugs, including 
pharmacoepidemiological studies to determine 
which drugs were to be prioritised in research 
endeavours. The Scottish Intercollegiate 
Guideline Development Network (SIGN)38 
(guideline 70) suggests the use of 
carbamazepine, sodium valproate, lamotrigine 
and oxcarbazepine as first line AEDs in 
the management of partial and secondary 
generalised seizures. Sodium valproate and 
lamotrigine are used as first-line drugs 
in the management primary generalised 
seizures, as well as in the case of doubt about 
the type of seizure or seizure syndrome. 
Level 1 evidence suggests that phenytoin, 
carbamazepine, sodium valproate, lamotrigine 
and oxcarbazepine have similar efficacy when 
used in the management of generalised 
tonic-clonic. The newer AEDs, lamotrigine 
and oxcarbazepine have a better safety and 
tolerability profile. Sodium valproate and 
lamotrigine are also used in the management 
of absence seizures and myoclonic seizures.  
Lamotrigine can worsen myoclonic seizures in 
some cases. Ethosuximide has been used for 
absence seizures in children for a very long 
time. Due to improved safety and tolerability 
profiles – especially with regard to fewer 
effects on cognition and behaviour, as well 
as the lack of interactions with other drugs, 
lamotrigine use may prove to be particularly 
advantageous in treating adolescents, young 
women and elderly persons with epilepsy. 
Pharmacokinetic modelling and population 
pharmacokinetics of antiepileptic drugs
Pharmacokinetic modelling is a powerful 
tool to study how demographic parameters, 
pathophysiological conditions, genetic factors 
and other sources of variability influence 
the dose-concentration relationship in such 
populations.16 The population PK approach 
allows the analysis of data from unbalanced 
designs and also from studies that are 
usually excluded from pharmacokinetic 
analysis, such as concentration data obtained 
from paediatric and elderly patients. Thus, 
population pharmacokinetic analysis plays 
an important role in individualization 
drug therapy in paediatric epilepsy. In 
traditional pharmacokinetic studies, the 
subjects are usually healthy volunteers 
or highly selected patients and the mean 
plasma concentration-time profile is the 
main focus of interest.  Pharmacokinetic 
modelling is thus useful in the determination 
of pharmacokinetic parameters in a specific 
patient population. This type of prediction 
of pharmacokinetic parameters is of great 
importance in order to individualize dosing 
regimen in a specific population such as 
paediatric epileptic population since epilepsy 
is a chronic neurological condition and 
developmental changes occur from childhood 
to adulthood. Many variables influence 
plasma drug concentrations of AEDs, and 
thus the pharmacokinetics of these drugs, 
especially in children. However, satisfactory 
pharmacokinetic models which allow accurate 
predictions of drug plasma concentrations 
still lack especially in paediatric populations 
and little published research has been found 
in this area. Most paediatric epileptiologists 
use ad hoc reasoning in the design of 
dosage regimens for AEDs in paediatric 
epilepsy. Pharmacokinetic software packages, 
such as Adapt® and NONMEM® are useful 
in the determination of pharmacokinetic 
parameters and can be very useful in a chronic 
neurological condition such as epilepsy.39
Conclusion
Epilepsy is a common neurological condition 
and research initiatives are being promoted 
at an international level, in order to address 
issues of drug development in epilepsy. This 
is a move in accordance with the WHO’s 2013 
report on ‘Priority Medicines for Europe and 
the World’, which emphasises the importance 
of addressing chronic non-communicable 
diseases which are characterised by high 
morbidity and mortality.40 This same 
document includes children among ‘special 
groups’ whose needs need to be addressed 
and in whom the management of illnesses 
needs to be prioritised. Children are a 
vulnerable population with unique health 
needs – physical, psychological and social. 
Their physiology is different from that of 
adults. Hence even the way their body is 
able to handle drugs differs from that of an 
adult. Parents play an important role in the 
healthcare management of young children 
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who are dependent. As children grow into 
adolescence they meet unique healthcare 
challenges, such as possible difficulties in 
adherence to therapy, especially when they 
begin to take control themselves over certain 
aspects of their healthcare such a taking their 
own medication on their own.
Population pharmacokinetics also 
play an important role in improving the 
therapeutic outcomes for paediatric 
populations with epilepsy, by contributing 
to the individualization of drug therapy and 
development of personalised medicine. It will 
thus lead to improved therapeutic outcomes 
and reduced adverse events in these patients. 
References
1. Sander JW, Hart YM. Epilepsy: Questions and Answers. 
Merit, 1999.
2. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, 
French J, Guilhoto L, et al. ILAE classification of the 
epilepsies: Position paper of the ILAE Commission 
for Classification and Terminology. Epilepsia. 
2017;58(4):512-521.
3. Wirrell, EC, Grossardt BR., Wong-Kisiel, LC, Nickels, KC. 
Incidence and classification of new-onset epilepsy 
and epilepsy syndromes in children in Olmsted 
Country, Minnesota from 1980 to 2004: a population-
based study. Epilepsy Res. 2011;95(1-2):110-118.
4. Berg, AT, Jallon, P, Preux, PM. The epidemiology 
of seizure disorders in infancy and childhood: 
definitions and classifications. Handb Clin Neurol. 
2013;111:391-398.
5. Soler D. Epilepsy in Maltese Children [dissertation]. 
Msida: University of Malta. 2000.
6. Gidal BE, Garnett WR. Epilepsy. In: Pharmacotherapy: 
a Pathophysiologic Approach. DiPiro JT, Talbert RL, 
Yee GC, Matzke GR, Wells BG, Posey LM (Eds.). New 
York: McGraw-Hill; 2005. p.1023-1048.
7. Wirrell EC. Predicting pharmacoresistance in pediatric 
epilepsy. Epilepsia. 2013;54 (Suppl 2):19-22. 
8. Brodie MJ. Antiepileptic drug therapy the story so 
far.  Seizure. 2010; 19(10):650-655.
9. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, 
Glauser, TA, Johannessen, SI, et al. Antiepileptic 
drugs-best practice guidelines for therapeutic drug 
monitoring: A position paper by the subcommission 
on therapeutic drug monitoring, ILAE Commission on 
Therapeutic Strategies. Epilepsia. 2008;49(7):1239-
1276.
10. Carmant L, Holmes GL, Sawyer S, Rifai N, Anderson 
J, Mikati MA. Efficacy of felbamate in therapy 
for partial epilepsy in children. J Pediatr. 
1994;125(3):481-486.
11. Bialer M, Johannessen SI, Kupferberg HJ, Levy 
RH, Perucca E, Tomson T. Progress report on new 
antiepileptic drugs: a summary of the Seventh Eilat 
Conference (EILAT VII). Epilepsy Res. 2004;61(1-
3):1-48.
12. Guerreiro MM, Vigonius U, Pohlmann H, de Manreza 
ML, Fejerman N, Antoniuk SA, et al. A double-blind 
controlled clinical trial of oxcarbazepine versus 
phenytoin in children and adolescents with epilepsy. 
Epilepsy Res. 1997;27(3):205-213.
13. Bourgeois BFD, Holder DL, Valencia I. Open label 
assessment of levetiracetam efficacy and adverse 
effects in a pediatric population. Epilepsia. 
2001;42(Suppl 7):253–254.
14. Hammoudi DS, Lee SS, Madison A, Mirabella 
G, Buncic JR, Logan WJ, et al. Reduced visual 
function associated with infantile spasms in children 
on vigabatrin therapy. Invest Ophthalmol Vis Sci. 
2005;46(2):514-520.
15. National Institute of Clinical Excellence. The 
epilepsies: the diagnosis and management of the 
epilepsies in adults and children in primary and 
secondary care. London: National Institute of Clinical 
Excellence. c2014. Available from: http://www.nice.
org.uk/guidance/cg137 Accessed 14 October 2014.
16. De Cock RFW, Piana C, Krekels EHJ, Danhof M, 
Allegaert K, Knibbe CAJ. The role of population 
PK-PD modelling in paediatric clinical research. Eur J 
Clin Pharmacol. 2011;67(Suppl 1):S5-S16.
17. Anderson GD, Lym AM. Optimizing paediatric 
dosing: a developmental pharmacological approach. 
Pharmacother. 2009;29(6):680-690. 
18. Perucca, E. Clinical pharmacokinetics of new-
generation antiepileptic drugs at the extremes of 
age. Clin Pharmacokinet. 2006;45(4):351-363.
19. Rosati A, De Masi S, Guerrini R. Antiepileptic Drug 
Treatment in Children with Epilepsy. CNS Drug 
2015;29(10):847-863.
20. Ette EI, Williams PJ. Population Pharmacokinetics 
I: Background, Concepts, and Models. Ann 
Pharmacother. 2004;38(10):1702-1706.
21. Perucca E. The clinical pharmacokinetics of the 
new antiepileptic drugs. Epilepsia. 1999;40(Suppl. 
9):S7–S13.
22. Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker 
RC, Perhach JL, et al. The effect of age on the 
apparent clearance of felbamate: a retrospective 
analysis using nonlinear mixed-effects modelling. 
Ther Drug Monit. 1996;18(1):19-29.
23. Ouellet D, Bockbrader HN, Wesche DL, Shapiro 
DY, Garofalo E. Population pharmacokinetics of 
gabapentin in infants and children. Epilepsy Res. 
2001;47(3):229-241.
24. Battino D, Croci D, Granata T, Mamoli D, Messina 
S, Perucca E. Single-dose pharmacokinetics of 
lamotrigine in children: influence of age and co-
medication. Ther Drug Monit. 2001;23(3):217-222.
25. Patsalos PN. Clinical pharmacokinetics of 
levetiracetam. Clin Pharmacokinet. 2004;43(11):707–
724.
26. May TW, Korn-Merker E, Rambeck B. Clinical 
pharmacokinetics of oxcarbazepine. Clin  
Pharmacokinet. 2003;42(12):1023-1042.
26. Patsalos  PN, Elyas AA, Ratnaraj N, Iley J. 
Concentration-dependent displacement of tiagabine by 
valproic acid. Epilepsia. 2002;43(suppl. 8):43.
27. Britzi M, Perucca E, Soback S, Levy RH, Fattore 
C, Crema F, et al. Pharmacokinetic and metabolic 
investigation of topiramate disposition in 
healthy subjects in the absence and in the 
presence of enzyme induction by carbamazepine. 
Epilepsia. 2005;46(3):378-384.
28. Scerri AM. Pharmacoepidemiology of epilepsy in a 
paediatric neurology clinic. University of Malta MSc 
Thesis; 2014.
29. Dörks M, Langner I, Timmer A, Garbe E. Treatment of 
Paediatric Epilepsy in Germany: Antiepileptic Drug 
Utilization in Children and Adolescents with a focus 
on new antiepileptic drugs. Epilepsy Res. 2013;103:45-
53.
30. Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, 
Guilliford MC. Trends in Antiepileptic Drug Utilisation 
in UK Primary Care 1993-2008: Cohort Study Using 
the General Practice Research Database. Seizure. 
2012;21:466-470. 
31. Hermann B, Seidenberg M, Bell B, Rutecki P, Sheth 
R, Ruggles K, et al. The neurodevelopmental impact 
of childhood-onset temporal lobe epilepsy on brain 
structure and function. Epilepsia. 2002;43(9):1062-71. 
32. Griffin S, Tranel D. Age of seizure onset, functional 
reorganization, and neuropsychological outcome 
in temporal lobectomy. J Clin Exp Neuropsychol. 
2007;29(1):13-24. 
33. Räty LKA, Wilde Larsson BM. Quality of life in young 
adults with uncomplicated epilepsy. Epilepsy Behav. 
2007;10:142-147.
34. Jacoby A, Baker GA. Quality-of-life trajectories in 
epilepsy: A review of the literature. Epilepsy Behav. 
2008;12:557-71.
35. Chung K, Liu Y, Ivey SL, Huang D, Chung C, Guo W, et 
al. Quality of life in epilepsy (QOLIE): Insights about 
epilepsy and support groups from people with epilepsy 
(San Francisco Bay Area, USA). Epilepsy Behav. 
2012;24:256-263.
36. Haag A, Strzelczyk A, Bauer S, Kühne S, Hamer HM, 
Rosenbow F. Quality of Life and Employment Status 
are Correlated with Antiepileptic Monotherapy versus 
Polytherapy, not with ‘Newer’ versus ‘Classic’ Drugs: 
Results of the ‘Compliant 2006’ Survey in 907 Patients. 
Epilepsy Behav. 2010;19:618-22.
37. Ceci A, Giaquinto C, Aboulker JP, Baiardi P, Bonifazi 
F, Della Pasqua O, et al. The Task-force in Europe for 
Drug Development for the Young (TEDDY) Network of 
Excellence. Paediatr Drugs. 2009;11(1):18-21.
38. Scottish Intercollegiate Guidelines Network. Diagnosis 
and management of epilepsy in adults. Edinburgh: 
Scottish Intercollegiate Guidelines Network. 2014. 
Available from: http://www.sign.ac.uk/pdf/sign70.pdf 
Accessed 18 October 2014.
39. Vucićević K , Miljković B, Pokrajac M, Prostran M, 
Martinović Z, Grabnar I. The influence of drug-drug 
interaction and patients’ characteristics on valproic 
acid’s clearance in adults with epilepsy using 
nonlinear mixed effects modelling. Eur J Pharm Sci. 
2009; 38(5):512-518. 
40. Kaplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthe 
B, Laing R. Priority Medicines for Europe and the 
World 2013 Update. World Health Organisation. 2013. 
Available from:  http://www.who.int/medicines/
areas/priority_medicines/MasterDocJune28_FINAL_
Web.pdf?ua=1 Accessed 28 July 2017
Key points
•	 Epilepsy is one of the most common neurological disorders, with approximately 45 per 
100,000 children developing new-onset epilepsy every year
•	 Children are a vulnerable population with unique health needs whose physiology is 
different from that of adults and thus handle drugs differently from adults
•	 The novel antiepileptic drugs have expanded the treatment options of epilepsy, 
however, they are also associated with pharmacokinetic shortcomings, especially for 
paediatric populations
•	 The correct use of these drugs can lead to improved quality of life measures
•	 The use of population pharmacokinetics addresses the challenges paediatric populations 
offer to drug and dose individualisation
